cas 25952-53-8|| where to buy 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

Nom du produit:1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

IUPAC Name:(3-{[(ethylimino)methylidene]amino}propyl)dimethylamine hydrochloride

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM303421-1000g	in stock	Ʃƅœ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 25952-53-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:25952-53-8; Formule moléculaire:C8H18ClN3; Point de fusion:-; Code SMILES:CCN=C=NCCCN(C)C.[H]Cl; Densité:

: Numéro de catalogue:CM303421; Poids moléculaire:191.7; Point d'ébullition:197.7°C at 760 mmHg; N° Mdl:MFCD00012503; Stockage:Keep in a dry and a tight container and store at 2°C~8°C

: Momelotinib; GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.